PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY
Abstract
Authors
P. Di Rienzo L. Zarrelli F.S. Mennini A. Marcellusi C. Bini B. Malcolm J. May K.M. Gooden G. Van de Wetering L.E. Smith van Carroll